C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy


– Initiates Phase 1 clinical study in patients with progressive supranuclear palsy

– Investigational recombinant anti-tau antibody represents lead clinical candidate in global C2N-AbbVie collaboration to address serious brain disorders

NORTH CHICAGO, Ill., July 17, 2015 /PRNewswire/ — C2N Diagnostics and AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). The companies also have begun a Phase 1 clinical study of C2N-8E12 in patients with PSP.

“The FDA’s orphan drug designation recognizes the lack of treatment options for patients with PSP, a debilitating neurological disease, and …
Read More →

AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer’s Disease Therapy

NORTH CHICAGO, Ill., March 19, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer’s Disease and other neurological disorders.  This partnership builds upon AbbVie’s commitment to pursue transformational disease-modifying therapies in Alzheimer’s Disease.

Tau stabilizes proteins that are responsible for the structure and transport in neuronal cells.
Abnormal accumulation of altered tau protein is a leading indicator in a variety of neurodegenerative conditions including Alzheimer’s Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration.  In these conditions, the development of tau pathology strongly …
Read More →

C2N Expands Partnership with Washington U to Commercialize Blood Test for Detection of Early AD

July 14, 2014

ST. LOUIS – C2N Diagnostics, LLC (C2N) today announced that it has expanded its partnership with Washington University School of Medicine (WUSM) in St. Louis. The objective of this collaboration is to commercialize a clinical blood test for detecting the earliest stages of Alzheimer’s disease (AD) as well as mild cognitive impairment (MCI). Under terms of the agreement, C2N has acquired the exclusive worldwide commercial license rights to a suite of technologies developed in the laboratories of Professors Randall Bateman, MD and David Holtzman, MD, in the Department of Neurology at WUSM.

The licensed technologies build upon the Stable Isotope Labeling Kinetics (SILK™) platform pioneered at WUSM and already marketed by …
Read More →

C2N Diagnostics Makes Three New Hires to Speed Commercialization of Diagnostics and Theranostics

Dr. Timothy D. Veenstra – Former Director of the Laboratory of Proteomics and Analytical Technologies at the National Cancer Institute – to lead effort as C2N’s New Senior Vice President of Diagnostic Sciences and Innovation

September 19, 2013

ST. LOUIS – C2N Diagnostics (C2N) today announced that it has added three highly accomplished individuals to its growing team of scientists and operators committed to bringing best-in-class biomarker tests to the market. These individuals will be focused on three primary objectives at C2N: (i) commercialize a clinical test for early detection of Alzheimer’s disease (AD) pathology; (ii) development and clinical validation of a pipeline of novel therapeutic and disease progression biomarkers; and (iii) laboratory quality control.

Timothy D. Veenstra, PhD, …
Read More →